Eculizumab Therapy Therapy with eculizumab was commenced at the discretion of the treating doctor. Eculizumab was administered as a every week intravenous infusion at a dosage of 600 mg for four weeks, accompanied by 900 mg every 2 weeks. The dosage or the frequency of use of eculizumab was elevated when there was proof breakthrough intravascular hemolysis. Your choice to initiate anticoagulation therapy in a patient was made at the discretion of the dealing with physician.The duration of therapy for sufferers in multiple-dose research ranged from 1-405 days with an average duration of 131 days and with 44 individuals treated for at least 12 months. Common adverse reactions include nausea, constipation, drowsiness and headache. Serious adverse events, including deaths, have been reported in sufferers with other immediate-launch transmucosal fentanyl products. The deaths occurred due to improper individual selection and/or improper dosing.
Annette McWilliams, M.B., Martin C.